Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Inflammatory Bowel Disease

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Inflamm Bowel Dis.

Yao J, Jiang X, You JHS

doi: 10.1093/ibd/izaa073.

RECOMMENDED

Inflammatory Bowel Disease

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Digestion.

Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology.

doi: 10.1159/000501930.

Inflammatory Bowel Disease

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Scand J Gastroenterol.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML

doi: 10.1080/00365521.

Inflammatory Bowel Disease

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Inflamm Bowel Dis.

Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ

doi: 10.1093/ibd/izaa102.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Aliment Pharmacol Ther.

Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G

doi: 10.1111/apt.15046.

Inflammatory Bowel Disease

Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures

BMC Gastroenterol.

Noiseux I, Veilleux S, Bitton A, Kohen R, Vachon L, White Guay B, Rioux JD

doi: 10.1186/s12876-019-0946-8.

Inflammatory Bowel Disease

Key insights from therapeutic drug monitoring in Crohn's disease patients

Expert Opin Drug Metab Toxicol.

Seinen ML, de Boer NK, van Bodegraven AA

doi: 10.1080/17425255.

Inflammatory Bowel Disease

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Inflamm Bowel Dis.

Fernandes SR, Bernardo S, Simões C, Gonçalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Tato Marinho R

doi: 10.1093/ibd/izz131.

Related content

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Inflammatory bowel disease patient perceptions of diagnostic and monitoring tests and procedures

Key insights from therapeutic drug monitoring in Crohn's disease patients

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease